Most Popular Stories
Poll
Featured Jobs
-
Dir/Quality Initiatives Job for Texas
StaffPointe, LLC - Fort Worth, TX -
Dir of Nursing/LTC Job for Kentucky
StaffPointe, LLC - Lexington, KY -
OB/GYN Job for Illinois
StaffPointe, LLC - near St. Louis, IL -
Director of Med/Surg Job for Maryland
StaffPointe, LLC - near D.C., MD -
Pediatrician
Executive Office Services - Philadelphia, PA
Events
Paid Research Reports
- Pricing and Reimbursement in Key Asia Pacific Markets
- Delivery Mechanisms for Large Molecule Drugs: Successes and failures of leading technologies and key drivers for market success
- The Cardiovascular Market Outlook to 2013: Competitive landscape, global market analysis and pipeline analysis
- Intellectual Property and Outsourcing in China: Minimizing risk whilst maximizing return on investment
- Health Care Equipment & Supplies: Global Industry Guide
- 2009 Trends to Watch: Healthcare Technology
Hot Topics >> Reader's Corners | Health plan CEO paychecks | Twitter | iPhone healthcare apps
Free Newsletter
FierceHealthcare is the leading source of healthcare management news for healthcare industry executives. Join 46,000+ healthcare industry insiders who get FierceHealthcare via daily email. Sign up today!
Popular Topics
- Medicare
- health plans
- Centers for Medicare and Medicaid Services (CMS)
- Insurance
- Food and Drug Administration (FDA)
- Electronic Medical Records (EMRs)
- Department of Health and Human Services (HHS)
- Medicaid
- American Medical Association (AMA)
- healthcare system
- prescription drugs
- UnitedHealth Group
- pharmaceutical companies
Stent study surprises
In potentially bad news for device manufacturers, a new study released today in the Journal of the American Medical Association finds that patients whose arteries are propped open with drug-eluting stents may have a much higher risk of developing blood clots than had previously been supposed. Patients tracked in the study had a 1.03 percent chance of developing a blood clot. The study tracked the progress of 2,400 patients in Germany and Italy. Johnson & Johnson's Cyper stent performed moderately better than Boston Scientific's Taxus. A Johnson & Johnson spokesman said the finding underscores the need for patients to receive the proper anti-clotting drugs.
For more on the stent study:
- see this story from the Boston Globe
Related Stories
- AMA tackles out-of-network fines by health plans
- American Hospital Association wants tougher reviews of health-plan mergers
- Antitrust laws could hobble healthcare reform
- Groups share details on $2T cost-savings offer
- Doctor gets jail time for out-of-state online prescribing
- AMA opposes government-backed healthcare
- Doctor of nursing practice exam challenged by some physicians
- AMA offers suggestions on cutting med school debt
- J&J to increase Cypher production
- ALSO NOTED: Boston Scientific stent sales down; AMA: Mergers in insurance industry hurting care; and much more...
Home
| Subscribe | Advertise | Mobile Edition | RSS |
Privacy
| Site MapTHE FIERCEMARKETS NETWORKFierceFinance | FierceFinanceIT | FierceComplianceIT | FierceHealthcare | FierceHealthFinance | FierceHealthIT | Hospital Impact | FierceMobileHealthcare | FierceCIO | FierceCIO:TechWatch | FierceContentManagement | FierceMobileIT | FierceGovernmentIT | FierceBiotech | FierceBiotech Research | FiercePharma | FierceVaccines | FierceBiotechIT | FiercePharma Manufacturing | FierceIPTV | FierceOnlineVideo | FierceTelecom | FierceVoIP | FierceBroadbandWireless | FierceDeveloper | FierceMobileContent | FierceWireless | FierceWireless:Europe© 2009 FierceMarkets, Inc. All rights reserved. |
![]() |






Click here to get the FierceHealthcare email newsletter for FREE!